Compare INFU & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFU | SPRO |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.8M | 156.3M |
| IPO Year | 2005 | 2017 |
| Metric | INFU | SPRO |
|---|---|---|
| Price | $9.19 | $1.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 245.3K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 181.82 | 111.81 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $143,436,000.00 | $66,802,000.00 |
| Revenue This Year | $3.20 | N/A |
| Revenue Next Year | $7.31 | $300.00 |
| P/E Ratio | $177.80 | ★ N/A |
| Revenue Growth | 6.36 | ★ 39.24 |
| 52 Week Low | $5.43 | $1.10 |
| 52 Week High | $11.04 | $3.08 |
| Indicator | INFU | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 18.94 |
| Support Level | $8.51 | N/A |
| Resistance Level | $10.04 | $2.44 |
| Average True Range (ATR) | 0.37 | 0.16 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 36.52 | 6.19 |
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.